Tokyo Tape
Sign in
← Nihon Chouzai

Quarterly report · Q3

3341.TEDINET S100Q7DI
Period2022-04-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥232.8bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥299.4bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥223.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥5.8bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥5.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥5.8bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥6.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥6.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥7.0bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥2.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.7bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.1bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥4.3bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥1.1bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥187.6bnat 2022-12-31Cons.Assets
Total assets¥178.8bnat 2022-03-31Cons.Assets
Total assets¥181.9bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥131.3bnat 2022-12-31Cons.Liabilities
Total liabilities¥125.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥56.3bnat 2022-12-31Cons.Net assets
Net assets / equity¥52.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥50.2bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥20.3bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥25.5bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥143.232022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥89.642022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥123.562021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥36.572021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.142021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio30.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio29.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio27.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 37
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥10.5bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥4.9bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥208.1bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥2m
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥10.6bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥5.9bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥602m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥29.3bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥18.9bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥10.4bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2022-04-01 → 2022-12-31−¥456m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-12-31¥243.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-12-31¥232.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-12-31¥10.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-12-31¥10.7bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥14.4bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥14.4bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥5.0bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥197.4bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥197.4bn
jpcrp040300-q3r_E05422-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥9.1bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥5.2bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥5.2bn
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥6m
jpcrp040300-q3r_E05422-000Medical Professional Staffing And Placement Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥423m
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥35.3bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥20.8bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥14.4bn
jpcrp040300-q3r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥1.3bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-12-31¥237.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-12-31¥223.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-12-31¥14.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-12-31¥10.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 364
ItemContextValueUnit
Liabilities and net assetsPrior1YearInstant178753000000JPY
Liabilities and net assetsCurrentQuarterInstant187619000000JPY
Net salesPrior1YTDDuration223439000000JPY
Net salesCurrentYTDDuration232844000000JPY
Cost of salesPrior1YTDDuration183714000000JPY
Cost of salesCurrentYTDDuration192233000000JPY
Gross profitPrior1YTDDuration39724000000JPY
Gross profitCurrentYTDDuration40610000000JPY
Selling general and administrative expensesPrior1YTDDuration33897000000JPY
Selling general and administrative expensesCurrentYTDDuration34780000000JPY
Operating incomePrior1YTDDuration5827000000JPY
Operating incomeCurrentYTDDuration5829000000JPY
Commission fee noiPrior1YTDDuration28000000JPY
Commission fee noiCurrentYTDDuration30000000JPY
Rent income noiPrior1YTDDuration372000000JPY
Rent income noiCurrentYTDDuration438000000JPY
Insurance income noiPrior1YTDDuration134000000JPY
Insurance income noiCurrentYTDDuration54000000JPY
Subsidy income noiPrior1YTDDuration164000000JPY
Subsidy income noiCurrentYTDDuration26000000JPY
Other noiPrior1YTDDuration269000000JPY
Other noiCurrentYTDDuration203000000JPY
Non operating incomePrior1YTDDuration969000000JPY
Non operating incomeCurrentYTDDuration753000000JPY
Interest expenses noePrior1YTDDuration229000000JPY
Interest expenses noeCurrentYTDDuration201000000JPY
Rent expense noePrior1YTDDuration285000000JPY
Rent expense noeCurrentYTDDuration330000000JPY
Other noePrior1YTDDuration224000000JPY
Other noeCurrentYTDDuration214000000JPY
Non operating expensesPrior1YTDDuration738000000JPY
Non operating expensesCurrentYTDDuration746000000JPY
Ordinary incomePrior1YTDDuration6058000000JPY
Ordinary incomeCurrentYTDDuration5836000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration6000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration1170000000JPY
Compensation income eiPrior1YTDDuration－JPY
Compensation income eiCurrentYTDDuration120000000JPY
Reversal of provision for directors retirement benefits eiPrior1YTDDuration46000000JPY
Reversal of provision for directors retirement benefits eiCurrentYTDDuration－JPY
Gain on transfer from business divestitures eiPrior1YTDDuration67000000JPY
Gain on transfer from business divestitures eiCurrentYTDDuration－JPY
Extraordinary incomePrior1YTDDuration120000000JPY
Extraordinary incomeCurrentYTDDuration1290000000JPY
Impairment loss elPrior1YTDDuration228000000JPY
Impairment loss elCurrentYTDDuration114000000JPY
Loss on sales of noncurrent assets elPrior1YTDDuration－JPY
Loss on sales of noncurrent assets elCurrentYTDDuration51000000JPY
Loss on disaster elPrior1YTDDuration3910000000JPY
Loss on disaster elCurrentYTDDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass